Our GMP saRNA-LNP manufacturing platform produces high-quality, potent saRNA and LNPs, accelerating the development of RNA therapies and vaccines.

uBriGene’s talented technical and regulatory teams have extensive experience in the GMP manufacturing and releasing self-amplifying RNA (saRNA) to support RNA therapies and vaccines. Our advanced LNP encapsulation technology ensures high encapsulation rate and well-controlled LNP size.

With our GMP saRNA production platform and optimized LNP RNA delivery technologies, we fast-track self-amplifying RNA (saRNA) manufacturing for scalable RNA-based therapies and RNA vaccines.
Integrated services, from plasmids to RNA lipid nanoparticles (LNP)
Polycistronic options
As a leader in saRNA technology, uBriGene delivers comprehensive solutions that foster innovation in RNA therapeutics development. Our advanced platforms enable seamless integration from plasmid template production to saRNA-LNP formulation, expediting the path to commercialization for RNA therapies.
uBriGene’s polycistronic saRNA enables the expression of multiple therapeutic genes from a single self-amplifying saRNA molecule. Additionally, we provide high-throughput RNA-LNP formulation studies to help identify the most effective LNP formulations for your therapeutic programs.

The integrated saRNA-LNP quality control and analytical testing within this platform guarantees that each batch meets the highest standards, ensuring safe and reliable therapeutic solutions for patients.
| Test Item | Method | |
|---|---|---|
| Identity | mRNA sequence identity | RT-PCR+Sanger Sequencing |
| Content | Concentration | UV absorbance |
| Purity | 5’ capping efficiency | CE/LC-MS |
| 3’ polyA tail length | CE/LC-MS | |
| A260/A280 | UV absorbance | |
| RNA integrity | HPLC | |
| mRNA fragments | ||
| Aggregate quantitation | ||
| Residual protein | Qubit / MicroBCA | |
| dsRNA | ELISA | |
| Residual DNA template | qPCR | |
| Residual solvents | Residual ethanol(GC-MS) | |
| Potency | Expression of target protein | Cell-based assay |
| Safety | Sterility | Culture method |
| Endotoxin | GEL-CLOT Method | |
| Physical/chemical Properties | Appearance | Visual method |
| pH | pH | |
*Outsourced testing
| Test Item | Method | |
|---|---|---|
| Identity | Identity of lipids | RP-HPLC |
| Integrity | LNP size and polydispersity | Dynamic light scattering (DLS) |
| Content | Concentration | Fluorescence-based assay |
| Purity | Aggregate quantitation | SEC-HPLC |
| Encapsulation efficiency | Fluorescence-based assay, | |
| Residual solvents | Residual ethanol | |
| Potency | Expression of target protein | Cell-based assay |
| Safety | Sterility | Culture method |
| Endotoxin | GEL-CLOT Method | |
| Physical/Chemical Properties | Appearance | Visual method |
| pH | pH | |
| Osmolality | Osmolality | |
| Subvisible particles | Light blockage methods | |
| Extractable volume | Volumetric method | |
*Outsourced testing
Request a QuoteIn our polycistronic saRNA design, multiple genes of interest (GOIs) can be expressed independently and in their native form, without the addition of extra amino acid sequences. The protein expression levels of the GOIs are identical.
This polycistronic saRNA could be beneficial for therapeutic programs requiring the expression of more than one protein.



Note: The same amount of saRNA and mRNA were used in this experiment. Due to its larger size, the molar concentration of saRNA is significantly lower compared to linear mRNA.
The polycistronic saRNA contains NeonGreen and RFP expression cassettes. The same amount of saRNA and mRNA (1ug, respectively) were transfected into HEK293 cells using PEI. Fluorescence images were captured 72 hours post transfection.

Lipid nanoparticles containing NeonGreen-teLuc saRNA, circRNA, and linear mRNA (1 pmol / 1E5 cells) were added to HEK293 cells, and Bioluminescence quantification was performed up to 16 days post-treatment.
Request a ConsultationUnveil uBriGene’s RNA and LNP manufacturing capacities and testing.
Learn more about our CAR-T CDMO manufacturing for high-quality therapies.
Discover our GMP plasmid manufacturing process and testing.
Discover how uBriGene accelerates iPSC-based therapeutics and cell therapies.
saRNA, or self-amplifying RNA, contains a gene of interest and the elements required for intracellular self-amplification, enabling prolonged protein expression from a relatively small amount of RNA. This can potentially support lower RNA doses compared with conventional mRNA approaches, depending on the application and formulation. uBriGene's saRNA platform supports therapeutic and vaccine development, including polycistronic saRNA designs for expressing multiple genes from a single molecule.
uBriGene can supply saRNA in single tubes suspended in nuclease-free water at 1 mg/mL. For saRNA-LNP products, RNA can be supplied in single tubes suspended in Tris buffer or PBS at 0.1 mg/mL RNA concentration. saRNA can be provided as bulk RNA or formulated into LNPs according to the requirements of the development program.
Typically, saRNA ranges from 8K to 13K nucleotides in length, but longer sequences can be produced if necessary.
uBriGene provides end-to-end saRNA manufacturing services, supporting both research-grade and GMP saRNA production. Its platform also supports GMP saRNA-LNP process development, manufacturing, and QC testing, using microfluidic LNP encapsulation technology that achieves >90% encapsulation efficiency. The platform supports integrated manufacturing from GMP plasmid template preparation through saRNA production and LNP formulation.
Because saRNA is substantially longer than conventional mRNA, maintaining RNA integrity during manufacturing and purification is a key challenge. uBriGene's GMP saRNA platform reports up to 80% saRNA integrity, with analytical testing including RNA integrity, fragments, aggregates, residual DNA, residual protein, dsRNA, and other quality attributes. Actual performance depends on the saRNA sequence and manufacturing process.
Yes, uBriGene can carry out LNP formulation studies, testing various lipids, components, and cell culture conditions to identify the most efficient delivery method for your target cells.
uBriGene supports GMP saRNA-LNP programs with regulatory and CMC support, including GMP manufacturing, QC testing, analytical characterization, and regulatory documentation. Its U.S. and Asia facilities support global cell and gene therapy programs, with an established DMF framework and an active FDA DMF #31266 for the Germantown, Maryland facility. Products tested at the site have also supported FDA IND clearances.
uBriGene's GMP saRNA manufacturing workflow can include GMP plasmid template preparation, saRNA production, purification, analytical and QC testing, LNP formulation, and product release. The integrated platform supports process development, manufacturing, and LNP formulation to help transition saRNA programs toward clinical development.
uBriGene's GMP saRNA QC testing includes sequence identity, concentration, 5′ capping efficiency, poly(A) tail length, RNA integrity, aggregates, residual protein, dsRNA, residual DNA template, residual solvents, potency, sterility, and endotoxin. saRNA-LNP testing includes lipid identity, particle size, PDI, concentration, encapsulation efficiency, potency, sterility, endotoxin, pH, osmolality, subvisible particles, and extractable volume
uBriGene's microfluidic LNP encapsulation technology achieves >90% encapsulation efficiency for saRNA-LNP production. LNP quality is further characterized by particle size, polydispersity index (PDI), concentration, aggregate content, potency, and other release and quality attributes.
Yes. uBriGene's polycistronic saRNA design enables multiple genes of interest to be expressed from a single self-amplifying RNA molecule. The platform is designed for programs requiring expression of more than one protein and can support therapeutic applications involving multiple gene products.
With our GMP saRNA production platform and optimized LNP RNA delivery technologies, we fast-track self-amplifying RNA (saRNA) manufacturing for scalable RNA-based therapies and RNA vaccines.
Integrated services, from plasmids to RNA lipid nanoparticles (LNP)
Polycistronic options
